Research by a group of scientists from Uppsala University in Sweden, published in the prestigious The New England Journal of Medicine, significantly changes the field of Type 1 diabetes treatment. They have overcome one of the main challenges—the necessity of suppressing a patient’s immune system due to transplanted cells.
In the study, a patient received genetically modified, beta-cell-like stem cells. These cells actively produced insulin in a way that the body’s immune system could not recognize them. Thanks to this innovative approach, the patient did not require immunosuppressive therapy, and the body showed no immune reaction to the foreign cells.
Stem Cell Therapy and Its Challenges
One of the most significant directions in Type 1 diabetes treatment is stem cell therapy. This includes the Zimislecel (VX-880) study, which describes the first and second phases of clinical trials. The goal of this method is to transplant insulin-producing cells into patients with Type 1 diabetes. Although the therapy has proven safe and effective, it still requires the use of immunosuppressive therapy. This is necessary because the patient’s immune system perceives the foreign cells as a potential threat and destroys them. Consequently, the main limitation of this method lies in the risks and side effects associated with immune system suppression.
Breakthrough: Avoiding Immunosuppression with Gene Engineering
To overcome this limitation, a second report published in the same journal announced a revolutionary development. Researchers used CRISPR gene engineering technology to create genetically modified cells. This technology altered the cells so that the immune system could no longer recognize them.
The study’s authors transplanted the modified stem cells into a patient with Type 1 diabetes. This is the main difference and a revolutionary achievement, as the patient did not require any immunosuppressive drugs. Twelve weeks after transplantation, the body showed no immune reaction to the foreign cells. Additionally, the patient’s C-peptide levels showed stable and glucose-responsive insulin secretion, which is direct evidence that the transplanted cells began functioning and effectively producing insulin.
Conclusion and Future Perspectives
These two studies reflect consistent progress in Type 1 diabetes treatment. While the first study confirmed the potential of stem cell therapy, the second one elevated this potential to a completely new level. Using CRISPR technology to avoid immunosuppression is a breakthrough that may one day finally cure Type 1 diabetes without weakening the immune system.
Reference:
Carlsson, P.-O., Hu, X., Scholz, H., et al. (2025). Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression. The New England Journal of Medicine.
Reichman, T.W., Markmann, J.F., Odorico, J., et al. (2025). Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. The New England Journal of Medicine.
